SCHEMBL23356009

SCHEMBL23356009

Cc1c(F)cccc1Nc1nc2[nH]nc(N)c2cc1F

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ OPRM1 P35372 1/20 0.38
▸ ILK Q13418 1/20 0.38
▸ PIK3CD O00329 2/20 0.36
▸ PIK3CG P48736 2/20 0.36
▸ PIK3CA P42336 2/20 0.36
▸ PIK3C2B O00750 1/20 0.36
▸ MTOR P42345 1/20 0.36
▸ PIK3CB P42338 1/20 0.36
▸ LRRK2 Q5S007 1/20 0.36
▸ PTK2 Q05397 1/20 0.35
▸ SGK1 O00141 1/20 0.35
▸ NUDT1 P36639 1/20 0.33
▸ PIM1 P11309 1/20 0.33
▸ CSNK2B P67870 1/20 0.33
▸ CSNK2A1 P68400 1/20 0.33
▸ PIM2 Q9P1W9 1/20 0.33
▸ KDR P35968 1/20 0.33
▸ LYN P07948 1/20 0.33
▸ BTK Q06187 1/20 0.33
▸ NTRK1 P04629 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30791283 1.00 OPRM1 (0.38) OPRM1ILKPIK3CDPIK3CGPIK3CA
SCHEMBL23356011 0.91 NUDT1 (0.43) PIK3CDPIK3CGPIK3CAPIK3CBNUDT1
SCHEMBL30791220 0.91 NUDT1 (0.43) PIK3CDPIK3CGPIK3CAPIK3CBNUDT1
SCHEMBL30791228 0.89 MAPT (0.44) KDREGFR
SCHEMBL23356026 0.89 MAPT (0.44) KDREGFR
SCHEMBL23356137 0.87 ZAP70 (0.36) ILKPIK3CDPIK3CGPIK3CAPIK3CB
SCHEMBL30791219 0.87 ZAP70 (0.36) ILKPIK3CDPIK3CGPIK3CAPIK3CB
SCHEMBL23369587 0.87 DHODH (0.42) PIK3CDPIK3CGPIK3CAPIK3C2BMTOR
SCHEMBL23356005 0.83 ILK (0.41) ILKKDRBTK
SCHEMBL23356139 0.83 EGFR (0.44) KDREGFR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12583852-B2 Heterocycle derivative JW PHARMACEUTICAL CORPORATION (KR) 2026-03-24 — — US disclosed
CN-112313232-B Novel heterocyclic derivatives JW中外制药公司 2024-03-08 — — CN disclosed
US-20220259199-A1 NOVEL HETEROCYCLE DERIVATIVE JW PHARMACEUTICAL CORPORATION (KR) 2022-08-18 — — US disclosed
EP-3822270-A1 NOVEL HETEROCYCLE DERIVATIVE JW Pharmaceutical Corporation (KR) 2021-05-19 — — EP disclosed
CN-112313232-A Novel heterocyclic derivatives JW中外制药公司 2021-02-02 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12583852-B2 Heterocycle derivative AR, SRD5A1, NR5A1 OPRM1 4546/4885ILK 1593/4885PIK3CD 2400/4885
US-20220259199-A1 NOVEL HETEROCYCLE DERIVATIVE AR, BRDT, NR5A1 OPRM1 4801/4885ILK 3880/4885PIK3CD 2107/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback